Succeeded in attracting 14 billion won worth of Series A investment
JNPMEDI
JNPMEDI announced that it has successfully completed attracting 14 billion won worth of Series A investment. It is the first achievement in 10 months since it received a seed investment of 2 billion won in January this year, and the cumulative investment amount reaches 16 billion won.
Succeeded in attracting 14 billion won worth of Series A investment
JNPMEDI (CEO Jeong Kwun-ho), a medical data platform company, announced on the 22nd that it has successfully completed attracting 14 billion won worth of Series A investment. This is the first achievement in 10 months since receiving a seed investment of 2 billion won in January this year, and the cumulative investment amount reaches 16 billion won.
The Series A funding was led by Pavilion Capital, a growth investment subsidiary of Temasek, Singapore's largest sovereign wealth fund, especially Kakao Ventures, Murex Partners, Ajou IB Investment, and Gentium Partners, which have been with them as early investors, high on JNPMEDI’s vision and participated in follow-up investments. It is noteworthy that all existing institutional investors have reinvested.
Founded in July 2020, JNPMEDI is a leading IT-based clinical trial data solution platform such as cloud and blockchain. The clinical trial sector, which has been less digitized than other fields, is an area with high demand for innovative technologies and is considered a promising industry with abundant growth potential.
JNPMEDI is a company that developed its own 'Maven Clinical Cloud' solution, a clinical trial data management platform that can be applied to various medical fields such as pharmaceuticals, bio, digital treatments, and digital medical devices, and has been attracting attention as a game changer in the decentralized clinical trials (DCT) market.
Starting with this investment attraction, J&P Medi plans to upgrade its products and enter the global market in earnest. First, significantly strengthen the data infrastructure and internal R&D organization. It also aims to become a professional software provider that presents global standards in the clinical market by strengthening cloud-based service stability and upgrading technology in a SaaS method.
"After the pandemic, non-face-to-face decentralized clinical trials have become a key trend in the global medical health industry," said Se-jin Kim, Chief of Digital Healthcare VC Investment Officer at Murex Partners. "We decided to invest in JNPMEDI, which is seeking new possibilities to expand the digital clinical trial market."
"We have added company-wide capabilities to lay the technical and service foundation for innovation in digital clinical trials," said CEO Kwun-ho Jeong. "We will introduce an all-in-one ecosystem that deals with everything about digital clinical trials based on the world's best technology."
Meanwhile, JNPMEDI is the first Korean company to join the DTRA (Decentralized Trials & Research Alliance), a common consultative body for global distributed clinical trials, and has focused on developing services based on international standards. Recently, it has taken the lead in leading the industry by successfully completing the nation's largest digital clinical trial symposium "JNPMEDI Connect 2022" and holding a meeting with top experts in the field of life science.